Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450697 | 1.00 | CHRNA7 (0.67) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL450696 | 1.00 | CHRNA7 (0.67) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL6625316 | 1.00 | CHRNA7 (0.67) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1761440 | 0.84 | CHRNA7 (0.60) | CHRNA7KCNH2 | |
| SCHEMBL6627648 | 0.80 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL5038489 | 0.80 | LMNA (0.45) | CHRNA7KCNH2 | |
| SCHEMBL4109513 | 0.80 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL4109510 | 0.80 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL4109514 | 0.80 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL6626087 | 0.80 | LMNA (0.45) | CHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619205-B1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | ABBVIE BAHAMAS LTD (BS) | 2017-05-17 | — | — | EP | disclosed |
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | disclosed |
| US-8987453-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2231672-B1 | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8853241-B2 | Biaryl substituted azabicyclic alkane derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2431368-B1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBVIE BAHAMAS LTD (BS) | 2014-08-27 | — | — | EP | disclosed |
| EP-2443122-B1 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2505588-B1 | process for preparing AMINOMETHYL AZAADAMANTANE DERIVATIVES as SELECTIVE MODULATORS OF THE ALPHA7- NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR (NNRS) | ABBVIE INC (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2129673-B1 | AMIMOMETHYL AZAADAMANTANE DERIVATIVES AND USE THEREOF AS SELECTIVE MODULATORS OF THE ALPHA7- NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR (NNRS) | ABBVIE INC (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2619205-A1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | AbbVie Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2069346-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009067586-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080262023-A1 | Aminomethyl Azaadamantane Derivatives and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080255178-A1 | Azaadamantane Ester and Carbamate Derivatives and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255180-A1 | 4-Substituted Azaadamantane Derivatives and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008118743-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | CHRNA7 1/4885KCNH2 1346/4885HTR3A 173/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | CHRNA7 2432/4885KCNH2 1014/4885HTR3A 1498/4885 |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | CHRNA7 2776/4885KCNH2 708/4885HTR3A 2305/4885 |
| US-20080255178-A1 | Azaadamantane Ester and Carbamate Derivatives and Methods of Use Thereof | CYP51A1, ALKBH5, AZI2 | CHRNA7 367/4885KCNH2 2406/4885HTR3A 1358/4885 |
| US-20080255180-A1 | 4-Substituted Azaadamantane Derivatives and Methods of Use Thereof | UGT1A4, CYP4B1, CYP4A11 | CHRNA7 1518/4885KCNH2 2951/4885HTR3A 383/4885 |
| US-20080262023-A1 | Aminomethyl Azaadamantane Derivatives and Methods of Use Thereof | TET3, DNMT1, TET1 | CHRNA7 2401/4885KCNH2 4083/4885HTR3A 915/4885 |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | CHRNA7 1/4885KCNH2 1346/4885HTR3A 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.